<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298283</url>
  </required_header>
  <id_info>
    <org_study_id>BRAPP2</org_study_id>
    <nct_id>NCT02298283</nct_id>
  </id_info>
  <brief_title>Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD</brief_title>
  <acronym>BRAPP2</acronym>
  <official_title>Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy brentuximab vedotin as consolidation treatment in
      patients with stage I/II Hodgkin's lymphoma and 18-fluorodeoxyglucose (FDG) -PET positivity
      after 2 cycles of ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to evaluate the progression free survival after treatment for patient with
      stage I/II supradiaphragmatic HL patient and PET positive after 2 courses of ABVD.

      The treatment consist of 3 phases :

        -  induction treatment with 2 cycles every 3 weeks of bleomycin, etoposide, Adriamycin,
           cyclophosphamide, oncovin, procarbazine, and prednisone (BEACOPP) escalated

        -  radiotherapy 30 Gy starting 3 to 4 weeks after last day of second course of
           BEACOPP-escalated

        -  consolidation treatment with 8 cycles every 21 days of brentuximab vedotin
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>PFS is defined as the time from the date of the first cycle of ABVD to the first observation of documented disease progression or death due to any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response rate (CR rate)</measure>
    <time_frame>35 weeks</time_frame>
    <description>according to Cheson 2007</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>study treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>induction = BEACOPP-escalated (bleomycin, etoposide, adriamycin, cyclophosphamide, oncovin, procarbazine, and prednisone) : 2 cycles every 3 weeks
radiotherapy = involved field radiotherapy (IFRT) will be given 3 to 4 weeks after the last day of second BEACOPP at 30 Grays (+boost 6 Grays to area with residual lesion) in 3 weeks
Consolidation = brentuximab vedotin treatment will start 4 weeks after the last day of IFRT and up to 6 weeks. The dose of study treatment is 1.8 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>is 1.8 mg/kg administrated by IV infusion</description>
    <arm_group_label>study treatment</arm_group_label>
    <other_name>SGN35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks</description>
    <arm_group_label>study treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <description>35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks</description>
    <arm_group_label>study treatment</arm_group_label>
    <other_name>Doxorubicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oncovin</intervention_name>
    <description>1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks</description>
    <arm_group_label>study treatment</arm_group_label>
    <other_name>Vincristin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks</description>
    <arm_group_label>study treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks</description>
    <arm_group_label>study treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procarbazine</intervention_name>
    <description>100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks</description>
    <arm_group_label>study treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks</description>
    <arm_group_label>study treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-CSF</intervention_name>
    <description>5 µg/kg/j, SC, D9 until GB 1.0x109/L</description>
    <arm_group_label>study treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>30 Grays</intervention_name>
    <description>30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.</description>
    <arm_group_label>study treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have histologically confirmed cluster of differentiation antigen 30+
             (CD30+) classical Hodgkin lymphoma

          2. Patients must have provided voluntary written informed consent

          3. Supradiaphragmatic Ann Arbor clinical stage I or II

          4. Mandatory PET scan performed at diagnosis

          5. Patients treated with first-line ABVD and PET scan positive after 2 cycles (Deauville
             score 4 &amp; 5)

          6. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             0-2

          7. Life expectancy &gt; 6 months

          8. Patients must be 18-65 years of age

          9. Patients must be available for periodic blood sampling, study-related assessments and
             management of toxicity at the treating institution

         10. Female patients who:

               -  Are postmenopausal for at least 1 year before the screening visit OR are
                  surgically sterile OR

               -  If they are of childbearing potential, agree to practice 2 effective methods of
                  contraception at the same time

         11. Male patients, even if surgically sterilized, who agree to practice effective barrier
             contraception during the entire study treatment period and through 6 months after the
             last dose of study drug, or agree to completely abstain from heterosexual intercourse

         12. Clinical laboratory values as specified below before the first dose of study drug:

               -  Absolute neutrophil count ≥ 1,500/µL

               -  Platelet count ≥ 75,000/ µL

               -  Total bilirubin must be &lt; 1.5 x the upper limit of the normal (ULN) unless the
                  elevation is known to be due to Gilbert syndrome

               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)must be &lt; 3 x
                  the upper limit of the normal range

               -  Serum creatinine must be &lt; 2.0 mg/dL and/or creatinine clearance or calculated
                  creatinine clearance &gt; 40 mL/minute

               -  Hemoglobin must be ≥ 8g/dL

         13. Patient affiliated to social security system

        Exclusion Criteria:

          1. Patients with dementia or altered mental status that would preclude compliance with
             drug delivery

          2. Women who are pregnant or breastfeeding

          3. Patients with symptomatic pulmonary disease

          4. Patients with known history of any of the following cardiovascular conditions:

               -  Myocardial infarction within 2 years of inclusion

               -  New York Heart Association (NYHA) Class III or IV heart failure

               -  Evidence of current uncontrolled cardiovascular conditions, including cardiac
                  arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic
                  evidence of acute ischemia or active conduction system abnormalities

               -  Recent evidence (within 6 months before first dose of study drug) of a
                  left-ventricular ejection fraction &lt;50%

          5. Any history of cancer or cancer treatment during the last 3 years with the exception
             of non-melanoma skin cancer or stage 0 (in situ) carcinoma of any type if they have
             undergone complete resection

          6. Uncontrolled infectious disease, including active Hepatitis B Virus (HBV) infection
             defined by either detection of Hepatitis B surface (HBs) Antigen or presence of
             Hepatitis B core (HBc) antibody without detectable anti HBs antibody

          7. Any active systemic viral, bacterial, or fungal infection requiring systemic
             antibiotics at the time of inclusion and planned to be still on going within 2 weeks
             prior to first study drug dose

          8. Known Human Immunodeficiency Virus (HIV), known or suspected hepatitis C Virus (HCV)
             or human T-cell lymphotrophic virus (HTLV) serology positivity

          9. Patients who have been treated previously with any anti-CD30 antibody

         10. Known hypersensitivity to any excipients contained in the brentuximab vedotin
             formulation

         11. Known cerebral or meningeal disease (HL or any other etiology), including signs or
             symptoms of Progressive Multifocal Leukoencephalopathy (PML)

         12. Any sensory or motor peripheral neuropathy greater than or equal to Grade 2

         13. Patients that have not completed any prior treatment chemotherapy and/or other
             investigational agents within at least 5 half-lives of last dose of that prior
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pauline BRICE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas GASTINNE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stéphanie DOYEN</last_name>
    <phone>+33 4 72 66 93 33</phone>
    <email>stephanie.doyen@lysarc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stéphane VINCENT</last_name>
    <phone>+33 4 72 66 93 33</phone>
    <email>stephane.vincent@lysarc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH Victor Dupouy</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Driss CHAOUI, MD</last_name>
      <email>driss.chaoui@ch-argenteuil.fr</email>
    </contact>
    <investigator>
      <last_name>Driss CHAOUI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier FITOUSSI, MD</last_name>
      <email>o.fitoussi@bordeauxnord.com</email>
    </contact>
    <contact_backup>
      <last_name>Olivier</last_name>
    </contact_backup>
    <investigator>
      <last_name>FITOUSSI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe FRUCHART, MD</last_name>
      <email>c.fruchart@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe FRUCHART, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Chambéry</name>
      <address>
        <city>Chambéry</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gian Mathéo PICA, MD</last_name>
      <email>gian-matteo.pica@ch-chambery.fr</email>
    </contact>
    <investigator>
      <last_name>Gian Mathéo PICA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand JOLY, MD</last_name>
      <email>bertrand.joly@ch-sud-francilien.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand JOLY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne HAIOUN, Prof</last_name>
      <email>corinne.haioun@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Corinne HAIOUN, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon - Hôpital le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CASASNOVAS, MD</last_name>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier CASASNOVAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital André Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan FARHAT, MD</last_name>
      <email>hfarhat@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>Hassan FARHAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katell LE DÛ, MD</last_name>
      <email>k.ledu@cjb72.org</email>
    </contact>
    <investigator>
      <last_name>Katell LE DÛ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER, Prof</last_name>
      <email>franck.morschhauser@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Franck MORSCHHAUSER, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed TOUATI, MD</last_name>
      <email>mohamed.touati@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Mohamed TOUATI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle NICOLAS- VIRELIZIER, MD</last_name>
      <email>emmanuelle.nicolas@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle NICOLAS- VIRELIZIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Réda BOUABDALLAH, MD</last_name>
      <email>bouabdallahr@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Réda BOUABDALLAH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Régis COSTELLO, Prof</last_name>
      <email>regis.costello@free.fr</email>
    </contact>
    <investigator>
      <last_name>Régis COSTELLO, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - Saint ELOI</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe QUITTET, MD</last_name>
      <email>p-quittet@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe QUITTET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GASTINNE, MD</last_name>
      <email>thomas.gastinne@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas GASTINNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline BRICE, MD</last_name>
      <email>pauline.brice@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pauline BRICE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bénédicte DEAU-FISCHER, MD</last_name>
      <email>benedicte.deau-fischer@cch.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Bénédicte DEAU-FISCHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean GABARRE, MD</last_name>
      <email>jean.gabarre@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean GABARRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Perpignan</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence SANHES, MD</last_name>
      <email>laurence.sanhes@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence SANHES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Krimo BOUABDALLAH, MD</last_name>
      <email>krimo.bouabdallah@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Krimo BOUABDALLAH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre Bénite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles SALLES, Prof</last_name>
      <email>gilles.salles@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles SALLES, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debre</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain DELMER, MD</last_name>
      <email>adelmer@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Alain DELMER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry LAMY de la CHAPELLE, Prof</last_name>
      <email>thierry.lamy.de.la.chapelle@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry LAMY de la CHAPELLE, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aspasia STAMATOULLAS, MD</last_name>
      <email>aspasia.stamatoullas@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Aspasia STAMATOULLAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc-Matthieu FORNECKER, MD</last_name>
      <email>luc-matthieu.fornecker@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Luc-Matthieu FORNECKER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>I.U.C.T Oncopole</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile BOREL, MD</last_name>
      <email>borel.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Cécile BOREL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjan ERTAULT, MD</last_name>
      <email>m.ertault@chu-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Marjan ERTAULT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serge BOLOGNA, MD</last_name>
      <email>s.bologna@chu-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Serge BOLOGNA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent RIBRAG, MD</last_name>
      <email>vincent.ribrag@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent RIBRAG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin lymphoma</keyword>
  <keyword>HL</keyword>
  <keyword>brentuximab vedotin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

